Effect of rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes

Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance

Philip A. Kern, Subramanian Ranganathan, Chunling Li et al. · American Journal of Physiology-Endocrinology and Metabolism · 2001 · 1.9K citations

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Philip Home, Stuart Pocock, Henning Beck‐Nielsen et al. · The Lancet · 2009 · 1.4K citations

Open-label Trial, Diabetes Management, Cardiovascular Disease +10

Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension

Inês Barroso, Mark Gurnell, Vivion Crowley et al. · Nature · 1999 · 1.4K citations · Full text

Insulin Resistance, Metabolic Syndrome, Genetic Determinant +13

Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people

Anoop D Shah, Claudia Langenberg, Eleni Rapsomaniki et al. · The Lancet Diabetes & Endocrinology · 2014 · 1.2K citations · Full text

Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes

Rodney A. Hayward, Peter D. Reaven, Wyndy L. Wiitala et al. · New England Journal of Medicine · 2015 · 657 citations · Full text